Bristol Myers unveils positive results for Reblozyl from Phase 3 COMMANDS study
The study evaluated the efficacy and safety of Reblozyl in treating anaemia due to very low-, low- or…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Nov 22
The study evaluated the efficacy and safety of Reblozyl in treating anaemia due to very low-, low- or…
31 Oct 22
Actemra is indicated for the treatment of hospitalised Covid-19 patients who are on systemic corticosteroids, and require supplemental…
31 Oct 22
The application was based on pivotal phase III data, which confirmed the vaccine's effectiveness against respiratory syncytial virus-related…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
28 Oct 22
Under the agreement, FDB will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød,…
28 Oct 22
Vabysmo is the first and only medication that targets and inhibits two disease pathways involving Ang-2 and VEGF-A…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
27 Oct 22
Capivasertib plus Faslodex showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS), compared to placebo…
27 Oct 22
However, the CRDAC panel did not support and voted 11-5 against the drug to be used in patients,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Oct 22
Tecvayli is an off-the-shelf, subcutaneous therapy, indicated for subcutaneous administration for the treatment of relapsed or refractory multiple…
26 Oct 22
Taysha Gene Therapies is engaged in developing gene therapies for the treatment of Rett syndrome and giant axonal…
25 Oct 22
The transaction is anticipated to close in the first quarter of 2023, subject to certain customary closing conditions,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates